Pharmacokinetics of Rosiglitazone in Patients with End-stage Renal Disease

Author： Thompson-Culkin K   Zussman B   Miller AK   Freed MI  

Publisher： Field House Publishing

ISSN： 0300-0605

Source： The Journal of International Medical Research, Vol.30, Iss.4, 2002-07, pp. : 391-399

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The pharmacokinetics (PK) of aprepitant are not affected in patients with end-stage renal disease (ESRD) or severe renal impairment

By  

Inpharma, Vol. 1, Iss. 1494, 2005-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Pharmacokinetics and Blood Pressure Response of Losartan in End-Stage Renal Disease

By Sica D.A.  

Clinical Pharmacokinetics, Vol. 38, Iss. 6, 2000-06 ,pp. : 519-526

Adis International

Access to resources Recommend Favorite

Epidemiology of end-stage renal disease

By Roderick Paul  

Clinical Medicine, Vol. 2, Iss. 3, 2002-05 ,pp. : 200-204

Royal College Of Physicians

Access to resources Recommend Favorite

Pathophysiology and Treatment of Hyperhomocysteinemia in End‐Stage Renal Disease Patients

By  

Hemodialysis International, Vol. 5, Iss. 1, 2001-01 ,pp. : 86-91

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacokinetics of remifentanil in end-stage renal failure

By  

Inpharma, Vol. 1, Iss. 1341, 2002-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite